Phase I study of RO6874281 in patients with advanced solid tumors
Latest Information Update: 23 Feb 2022
At a glance
- Drugs Simlukafusp alfa (Primary) ; Atezolizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 22 Feb 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
- 04 Jan 2022 New trial record